Cryoport
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Cryoport disclosed its preliminary financial results for the second quarter ending on June 30, 2023, on July 12, 2023. The announcement revealed that the estimated total revenue for the second quarter of 2023 is anticipated to range between $56.5 and $57.5 million. This represents an 11% decrease at the midpoint compared to the same quarter in 2022. The disclosed reasons for these results include weaker global demand for capital equipment, delays in clinical trial starts, and slower-than-expected progress from specific clients. Consequently, the Company’s stock price experienced a decline in response to this information.
